The Experimental and Computational Genomics Core (ECGC) is a newly created Core that integrates all of the cancer genomics services in the Sidney Kimmel Comprehensive Cancer Center (SKCCC). The primary mission of the Core is to allow SKCCC investigators to harness the ongoing revolution in cancer genomics to accelerate their basic discovery and translational research. The ECGC has streamlined services that were previously offered through three separate Cores: the Microarray Core, Next-Generation Sequencing Core and Bioinformatics Core. The new joint structure recognizes that the activities of the previous three Cores are highly interdependent and formalizes a long-standing commitment to coordinate computing resources, hiring and educational activities for the common good of the SKCCC. The newly created centralized structure has streamlined access to experimental and computational genomics technologies and expertise, and enhanced opportunities for didactic and hands-on education in both the experimental and computational aspects of cancer genomics. The immense laboratory and analytical expertise brought together in the newly integrated cross-disciplinary Core are now available, in a single and clearly defined Core, to all SKCCC investigators. The services provided by this Core are not available elsewhere. An SKCCC member looking to outside resources would need to independently talk with multiple vendors and would only be able to obtain piecemeal services. This Core is led by Leslie Cope, Ph.D.; Sarah Wheelan, M.D., Ph.D.; and Srinavasan Yegnasubramanian, M.D., Ph.D., who bring together multidisciplinary expertise in genomics technologies, computational biology and biostatistics/bioinformatics. The Core provides access to, and education in, state-of-the-art, next- generation sequencing, microarray technologies and analytical workflows for probing genomic alterations (including SNVs, indels and structural alterations), cancer epigenomics (e.g., ChIP-seq and DNA methylome), transcriptomics and metagenomics. For each project, the Core uses a multidisciplinary clinic model to establish and execute an experimental and analytical plan, first meeting with each investigator and then helping them through all aspects of their genomics experiments, including experimental design, high-throughput microarray or next-generation sequencing workflows, and computational/bioinformatics data analysis. Additionally, the Core provides extensive educational resources, including short courses, workshops and a symposium, so that investigators can gain the skills they need to fully understand and utilize the data and analyses generated. The success of this Core is evidenced by the high level of usage across nearly all Programs and the cited support in a large number of impactful publications, national/international conference abstracts and successful grant applications. SKCCC Managed Core Reporting Period: Jan. 1, 2015, to Dec. 31, 2015

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA006973-55S2
Application #
9734247
Study Section
Subcommittee I - Transistion to Independence (NCI)
Program Officer
Belin, Precilla L
Project Start
Project End
Budget Start
2018-05-01
Budget End
2019-04-30
Support Year
55
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Johns Hopkins University
Department
Type
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21205
Giraldo, Nicolas A; Nguyen, Peter; Engle, Elizabeth L et al. (2018) Multidimensional, quantitative assessment of PD-1/PD-L1 expression in patients with Merkel cell carcinoma and association with response to pembrolizumab. J Immunother Cancer 6:99
Barberi, Theresa; Martin, Allison; Suresh, Rahul et al. (2018) Absence of host NF-?B p50 induces murine glioblastoma tumor regression, increases survival, and decreases T-cell induction of tumor-associated macrophage M2 polarization. Cancer Immunol Immunother 67:1491-1503
Taube, Janis M; Galon, Jérôme; Sholl, Lynette M et al. (2018) Implications of the tumor immune microenvironment for staging and therapeutics. Mod Pathol 31:214-234
Krueger, Timothy E G; Thorek, Daniel L J; Denmeade, Samuel R et al. (2018) Concise Review: Mesenchymal Stem Cell-Based Drug Delivery: The Good, the Bad, the Ugly, and the Promise. Stem Cells Transl Med 7:651-663
Boudadi, Karim; Suzman, Daniel L; Anagnostou, Valsamo et al. (2018) Ipilimumab plus nivolumab and DNA-repair defects in AR-V7-expressing metastatic prostate cancer. Oncotarget 9:28561-28571
Dean, Lorraine T; Gehlert, Sarah; Neuhouser, Marian L et al. (2018) Social factors matter in cancer risk and survivorship. Cancer Causes Control 29:611-618
Yuan, Ming; Da Silva, Ana Cristina A L; Arnold, Antje et al. (2018) MicroRNA (miR) 125b regulates cell growth and invasion in pediatric low grade glioma. Sci Rep 8:12506
Jacobs, Michael A; Macura, Katarzyna J; Zaheer, Atif et al. (2018) Multiparametric Whole-body MRI with Diffusion-weighted Imaging and ADC Mapping for the Identification of Visceral and Osseous Metastases From Solid Tumors. Acad Radiol 25:1405-1414
Annesley, Colleen E; Rabik, Cara; Duffield, Amy S et al. (2018) Knock-in of the Wt1 R394W mutation causes MDS and cooperates with Flt3/ITD to drive aggressive myeloid neoplasms in mice. Oncotarget 9:35313-35326
Liu, Tao; Ivaturi, Vijay; Sabato, Philip et al. (2018) Sorafenib Dose Recommendation in Acute Myeloid Leukemia Based on Exposure-FLT3 Relationship. Clin Transl Sci 11:435-443

Showing the most recent 10 out of 2393 publications